Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial
April 17th 2019The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
Read More
New Treatment for Osteoporosis In Postmenopausal Women is Available
April 16th 2019Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Read More
Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval
April 16th 2019Estimates suggest that by 2020, 1.5 to 1.75 million people in the U.S. will be living with wet AMD, a leading cause of blindness worldwide and a rapidly growing public health concern, according to Novartis.
Read More
Plants May Offer Prevention Benefits for Vision Loss in Patients with Diabetes
April 12th 2019A study, which tested naturally occurring homoisoflavonoids found in the Hyacinthaceae plant family and their synthetic derivatives, focused on the abnormal growth of new blood vessel cells in the eye that are linked to types of blindness.
Read More